The CD28.6 antibody reacts with human CD28, a 44 kDa type I surface glycoprotein which acts as a co-stimulatory receptor in support of the T cell receptor (TCR). CD28 exists as a homodimer with specificity for two known ligands, known as B7-1 (CD80) and B7-2 (CD86), which are expressed on activated B cells and antigen-presenting cells. These ligands trigger CD28 signaling in concert with TCR activation to drive T cell proliferation, induce high-level expression of IL-2, impart resistance to apoptosis, and enhance T cell cytotoxicity. The interaction / co-stimulatory signaling between the B7 ligands and CD28 provides crucial communication between T cells and B cells or APCs to coordinate the adaptive immune response. The CD28.6 antibody is reported to have neutralizing activity and is also useful for western blotting.

Type: Primary
Antigen: CD28
Clonality: Monoclonal
Clone: CD28.6
Conjugation:
Epitope:
Host: Mouse
Isotype: Mouse IgG2a, kappa
Reactivity: Human